Replies to post #701 on Accuray Inc (ARAY)

[grantg2]

plfm... Yes, this is one of the news releases

I was looking forward to seeing the company issue regarding the FACTS about SRS. I hope it is a "shot across the bow" and shows ARAY is going to become MUCH MORE AGGRESSIVE in challenging the gibberish put out by dual-use competitors that claim to be SRS devices!

Perhaps the company has been waiting for this study to give numbers to stand alongside the visual demonstrations (animations) that many have called for them to begin developing to graphically show what is very confusing to analysts when given the details by complex technical explanations that none seem able to follow!

Also addressed in this excerpt posted by PauvrePavillion elsewhere:

"1. Take a more aggressive and effective approach to technology explanation and differentiation.

We're in the SRS business. Most analysts still don't even know that. They think we're in the radiotherapy business. The smoking gun? There is not one mention of SRS in the UBS report. Dr. Thomson's verbal explanations are not getting it done. We need a compelling animated video now."

This would be a great combination of materials to get out to the investment community... the data underlying this PR today... and an animation such as PP is calling on the company to produce and distribute widely to the investment community.

Imagine this SRS comparison as the ARAY campaign for investor awareness this year...

and by next year the preliminary results of Roth-Anderson should become available. By that time perhaps HALF of the 1200-2000 cases of early detection lung cancer would be collated for preliminary evaluation & discussion of those "preliminary results!"

Then, by the time another 6-8 months of data with similar outcomes would be incorporated, we would have another good PR to release about CK's efficacy compared to open thorax surgery for lung cancer.

The future for patients and investors who are involved with ARAY & CyberKnife should be very rewarding. IMO...